Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland

详细信息	查看全文 | 推荐本文 |

• 作者：Timo Purmonen ; Janne A. Martikainen ; Erkki J.O. Soini ; Vesa Kataja ; Riikka-Liisa Vuorinen ; Pirkko-Liisa Kellokumpu-Lehtinen
• 关键词：costs ; cost analysis ; cost-effectiveness analysis ; Finland ; renal cell carcinoma ; sunitinib
• 刊名：Clinical Therapeutics
• 出版年：2008
• 期刊代码：65_01492918
• 类别：med
• 出版时间：February 2008
• 卷：30
• 期：2
• 页码：382-392
• 文件大小：838 K

摘要

Background: Cytokine therapy is currently used as first-line treatment of metastatic renal cell carcinoma (mRCC). Until recently, treatments with proven efficacy after the failure of first-line cytokine therapy were not available. In recent clinical trials, sunitinib has been associated with good response rates in patients with mRCC.